Lassa vaccine
US11976305B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 20, 2018 |
| Grant date | May 7, 2024 |
| Priority date | — |
| Expiry date | Dec 20, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18471
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.